Taken together, these data suggest that XIST can inhibit miR-29c expression by directly binding to miR-29c and subsequently up-regulate the expression of SP1 and MGMT to promote the chemoresistance of glioma cells to TMZ. The gene discussed is XIST; the disease is central nervous system cancer.